Work

Whole-body photobiomodulation therapy in Parkinson's disease: a single-arm feasibility and safety pilot trial with exploratory cognitive signals

Year: 2026
Type: preprint
Study design: Clinical Trial
Abstract: Background Beyond dopaminergic loss, Parkinson's disease (PD) involves mitochondrial dysfunction, ATP/NAD⁺ depletion, neuroinflammation, and reduced cerebral perfusion. Photobiomodulation (PBM)—red and near-infrared light absorbed by mitochondrial cytochrome c oxidase—raises ATP synthesis, increases nitric-oxide–mediated blood flow, and reduces inflammation, and so could act on several of these pathways at once. In PD, PBM has been applied almost exclusively transcranially; whole-body PBM (WB-PBM) has not been evaluated. We conducted an early-phase pilot to characterise its safety, feasibility, and preliminary effects ahead of a future sham-controlled trial. Methods This single-centre, single-arm, prospective pilot trial enrolled 15 patients with idiopathic PD (Hoehn & Yahr 1–3); 14 completed 30 WB-PBM sessions (660/810/850/930 nm; skin-surface irradiance 35–65 mW/cm²; 20 min; three times weekly for 10 weeks). The pre-specified registered primary efficacy outcome was the UPDRS total score; exploratory motor and cognitive outcomes were also assessed. Pre–post changes used the Wilcoxon signed-rank test (effect size r = Z/√N), with Benjamini–Hochberg false-discovery-rate (FDR) correction applied within a pre-specified memory family (SVLT, RCFT). Results The registered primary outcome, UPDRS total, fell from 24.86 ± 15.98 to 20.29 ± 8.71—a moderate-sized reduction (r = − 0.42) that did not reach significance in this small sample (p = 0.127). Within the memory family, verbal learning improved with a large effect and survived FDR correction: SVLT total score (r = − 0.74; p = 0.006; p_adj = 0.041) and its constituent immediate recall (r = − 0.69; p = 0.009; p_adj = 0.041). Visuospatial memory (RCFT immediate recall, delayed recall, total score) also improved with large effects, significant before but not after correction (all p_adj = 0.076). Motor outcomes were maintained without deterioration. One participant had mild localised hyperpigmentation, judged unrelated to the study device and resolving during the study; no serious adverse events occurred. Conclusions WB-PBM was safe and feasible in PD. Verbal memory improved robustly enough to survive FDR correction, visuospatial memory showed a promising signal requiring confirmation, and the registered primary outcome showed a non-significant, moderate-sized reduction. A sham-controlled randomised trial should follow. Trial registration ClinicalTrials.gov, NCT07271927 (https//clinicaltrials.gov/study/NCT07271927) registered 9 December 2025 retrospectively registered (first participant enrolled 12 February 2025).
Language: English
Field: Medicine
Open Access status: green
OpenAlex ID: W7236072454
Cites: 45
Cited by:
Related to: 10